Chiesi Global Rare Diseases, a business unit of the Chiesi Group, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), have requested a re-examination of the recent negative opinion issued by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback